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The molecular genetic mechanisms underlying esophageal cancer are poorly understood. However, a novel
gene that may be involved in esophageal carcinogenesis was recently localized by others to distal 17q by
linkage analysis of kindreds with palmoplantar keratoderma and squamous cell carcinoma of the esophagus.
To help determine whether a distal 17q gene may also be involved in the pathogenesis of primary Barrett’s
esophageal and gastric cardia adenocarcinomas, we performed loss of heterozygosity (LOH) analysis of 21
Barrett’s and 18 gastric cardia adenocarcinomas at loci spanning 17q: cen—BRCA1—SSTR2—D17S2058—
D17S929—D17S722—D17S937—D17S802—tel. Over 50% of the Barrett’s and cardia adenocarcinomas demon-
strated loss of an allele at one or more informative distal 17q markers. One common overlapping region of loss
involved loci mapped to distal 17q24–proximal 17q25, which tentatively defines a potential chromosomal
region distal to BRCA1 involved in the pathogenesis or progression of both types of adenocarcinomas. LOH
analysis of DNA from matched microdissected sections of Barrett’s metaplasia suggested that loss of D17S2058
in this region may be an early event in the malignant transformation of Barrett’s metaplasia. No statistically
significant correlations between 17q LOH and tumor stage or patient survival were noted. In summary, LOH
mapping of 17q in Barrett’s and cardia adenocarcinomas suggests the existence of at least one putative distal
17q tumor suppressor gene involved in the pathogenesis of these tumors. Mol. Carcinog. 22:222–228, 1998.
© 1998 Wiley-Liss, Inc.
Key words: tumor suppressor gene; loss of heterozygosity; malignancy; cancer; gene mapping
INTRODUCTION
The incidence and mortality rates of esophageal
adenocarcinoma continue to rise for men in the
United States, in contrast to the decreasing incidence
reported for many other types of solid tumor malig-
nancies [1,2]. Unfortunately, relatively little is known
about the multistep molecular mechanisms under-
lying this disease as compared with those of other
solid tumor malignancies. It has been demonstrated
that esophageal adenocarcinomas often arise from
Barrett’s columnar metaplasia of the esophagus,
which is thought to be acquired secondary to chronic
gastroesophageal reflux [3,4]. It is estimated that
approximately 10% of individuals with Barrett’s
esophageal metaplasia may undergo malignant trans-
formation of the esophagus [3]. At present, many of
the critical genetic and nongenetic factors underly-
ing this malignant transformation remain unclear.
We hope that improved understanding of the mo-
lecular genetic events predisposing individuals to
increased susceptibility for malignant transformation
will facilitate improved diagnostic testing and prog-
nostic management for affected individuals and
individuals at risk. Pathological and immunohis-
tochemical analyses with p53 and intestinal enzyme
expression suggested that molecular changes consis-
tent with Barrett’s adenocarcinoma are also present
in adenocarcinomas of the gastric cardia (gastro-
esophageal junction) [5–7], suggesting that similar
genetic mechanisms may underlie the development
of both tumor types.
Several genes are hypothesized to play a role in
the progression of esophageal carcinogenesis (includ-
ing the TP53, CDKN2, and APC genes) based on ge-
netic studies, but it is quite likely that additional
as-yet-unidentified genes may also be involved [8–
19]. The development of esophageal and gastric car-
dia tumors is thought to reflect a clonal multistep
process involving the accumulation of mutations in
growth regulatory genes, similar to the multistep
process of tumorigenesis so elegantly described for
colorectal cancer [20]. Linkage analysis of kindreds
with palmoplantar keratoderma and esophageal
squamous cell carcinoma localized a novel gene for
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this syndrome to 17q24–25 [21–24]. We have also
mapped a putative tumor suppressor gene or genes
involved in breast and ovarian cancer distal to 17q25
by loss of heterozygosity (LOH) studies [25,26]. LOH
studies, most often in concert with other associated
positional cloning strategies, have provided critical
localization information for the cloning of several
tumor suppressor genes [27].
To date, there have been few detailed LOH studies
of distal 17q in esophageal and gastric cardia neo-
plasms, and most have been limited to proximal 17q,
where BRCA1, the culprit gene for familial early-on-
set breast and ovarian cancer, resides. No detailed
LOH studies of distal chromosome 17q have been
published. We analyzed esophageal and gastric car-
dia tumors for LOH on 17q to help determine the
potential roles, if any, of putative distal 17q tumor
suppressor genes in the pathogenesis of these tumors
and to determine if the same 17q24-25 genetic re-
gion demonstrating linkage to squamous cell carci-
noma of the esophagus associated with palmoplantar
keratoderma demonstrates LOH in sporadic esoph-
ageal and cardia adenocarcinomas. We also wanted
to determine whether the discrete region of 17q25
LOH we previously detected in breast and ovarian
neoplasms is also lost in esophageal and gastric car-
dia tumors, which would suggest localization of a
novel tumor suppressor gene involved in multiple
solid tumors and akin to some of the cell-cycle regu-
lators like p16 [28].
MATERIALS AND METHODS
Samples
DNA samples from 21 Barrett’s esophageal adeno-
carcinomas and 18 gastric cardia tumors were ex-
tracted from dissections of frozen tissue obtained at
the time of esophagotomy at the University of Michi-
gan Medical Center. Each patient’s age at diagnosis,
sex, tumor type, TNM stage, and months of survival
(based on last follow-up examination) after diagno-
sis were recorded. Careful pathological analysis of
tumor margins on 5-µm cryostat sections was con-
ducted before careful dissection of frozen tumor tis-
sue specimens to enrich for the targeted tumor tissue.
DNA was extracted by standard methods as previ-
ously described [15]. The tumor cell nuclei content
of each sample, estimated by microscopic analysis
of tumor specimens and margins, exceeded 80%.
Samples demonstrating more than 20% stromal and
normal inflammatory cells were not used for LOH
analysis to avoid uninterpretable results due to sig-
nificant admixture of normal cells in tumor samples.
Matched normal DNA samples were extracted from
normal esophageal or gastric tissue by using stan-
dard techniques previously reported [15]. For 11 of
the Barrett’s adenocarcinomas, matched DNA
samples were also prepared from minute discrete re-
gions of Barrett’s metaplastic epithelium. These speci-
mens were microdissected from normal tissue on
5-µm cryostat sections under a dissecting microscope
to enrich for metaplastic cells by using previously
reported methods [26]. Using this method of micro-
dissection, we were able to obtain samples in which
well over 90% of the nuclei were from Barrett’s meta-
plastic cells.
LOH Analysis
Polymerase chain reactions (PCRs) of matched tu-
mor and normal pairs were conducted with eight
chromosome 17q polymorphic markers [29] (Table
1) in which one primer was end-labeled with T4 poly-
nucleotide kinase and [γ32P]dATP. The PCR anneal-
ing conditions used were based on optimized
conditions for LOH previously reported [26]. Samples
were electrophoresed at 70 W on 5% denaturing
formamide-containing polyacrylamide gels and ex-
posed to x-ray film from 0.5–72 h to generate light
and dark exposures for all gels. LOH was visually
scored by two independent observers when an allele
was absent or clearly displayed a markedly decreased
signal intensity in tumor tissue. Tumors that visu-
ally exhibited a reduction in signal intensity but not
complete absence were also subjected to digital
densitometry analysis (Alpha-Inotech Corporation)
to calculate allelic imbalance ratios to confirm our
visual inspection. When over 50% allelic imbalance
was detected in tumor alleles compared with nor-
mal tissue alleles, the tumor was characterized as
Table 1. 17q Loci Analyzed in Esophageal and Gastric Cardia Tumors
Locus Primers* Heterozygosity frequency† Map location‡
BRCA1 AFM248yg9 0.80 17q21
BRCA1 s975 0.65 17q21
SSTR2 SSTR2 1/5 0.88 17q24
D17S2058 CTT16 0.78 17q24-25
D17S929 AFM074zf7 0.60 17q24-25
D17S722 nm00060up 0.84 17q25
D17S937 AFM107ye3 CA/GT 0.72 17q25
D17S802 AFM210xa5 CA/GT 0.82 17q25
*Primer sequences and general amplification conditions are from the Online Genome Data Base [29] (http://gdbwww.gdb.org/).
†Heterozygosity frequencies were calculated from our laboratory data set.
‡Loci are listed from proximal to distal 17q based on database reports [29,30] and our physical mapping (unpublished data).
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having LOH. In all cases, densitometry analyses were
concordant with visual inspection.
RESULTS
The LOH patterns for distal 17q loci in both
Barrett’s esophageal and gastric cardia adenocarci-
nomas were strikingly similar, as demonstrated in
Figure 1A and B. No LOH was seen in three squa-
mous cell carcinomas analyzed in the same manner
(data not shown). Most of the samples provided
clearly interpretable LOH results, as shown in Figure
2. Most of the tumors had clear regions of allelic loss
and regions of allelic retention, indicating that our
dissected samples provided adequate enrichment of
tumor tissue for LOH analysis (Figure 2). For tumor
samples in which no LOH was present at any of the
analyzed loci, it is difficult to say with absolute cer-
tainty whether admixture of normal cells in the tu-
mor samples may have hampered detecting regions
of LOH. It is possible that the LOH rate may have
been underestimated, because some samples may
not have exhibited detectable LOH because of ad-
mixture of normal cells. However, given that visual
inspection of cryostat sections of these tumors and
estimation of their tumor nuclei content showed
that these tumors were not different from tumors
in which clear LOH was noted, we are confident
that our results accurately represent the true LOH.
In fact, only in a minority of informative tumor
samples, less than 2%, could we not determine with
confidence whether or not allelic imbalance was
present even after reamplification and reanalysis
of samples. This was most often due to poor am-
plification of the tumor sample.
The overall rates of LOH for seven loci in all tu-
mors studied are presented in Table 2 and varied from
a low rate of four of 32 informative tumors (12.5%)
at BRCA1 (when data for both informative markers
are combined) to the highest rates of seven of 20
informative tumors (35%) at D17S929 and 12 of 36
informative tumors (33%) at D17S2058 (Figure 2).
Eleven Barrett’s adenocarcinoma samples (numbers
8, 10, 18, 22, 26, 28, 30, 32, 83, 89, and 92) were also
compared with available matched microdissected
specimens representing potentially premalignant
Barrett’s metaplastic epithelium at loci where LOH
was present in the tumor specimen. Concordant LOH
was seen in the matched premalignant Barrett’s epi-
thelium and adenocarcinoma samples for tumor
sample 10 at D17S2058 (Figure 3) and tumor sample
30 at D17S722 and tumor sample 92 at BRCA1 (data
not shown). Interestingly, the matched premalignant
Barrett’s epithelium sample for adenocarcinoma
sample 22 was concordant for LOH at D17S2058 but
was discordant with the matched adenocarcinoma
at informative flanking loci, as the tumor but not
the premalignant Barrett’s specimen demonstrated
LOH at these loci.
Each patient’s age, sex, tumor stage, and months
of survival after diagnosis at last follow-up are also
presented in Figure 1A and B. Most of the samples,
86% of the Barrett’s adenocarcinomas and 89% of
the cardia adenocarcinomas, were from male pa-
tients. It is interesting that the average age at diag-
nosis for men with Barrett’s adenocarcinomas was
63.5 yr, whereas the average age of onset for the
women with Barrett’s adenocarcinomas was much
higher (78 yr; not statistically significant). The aver-
age age at diagnosis of cardia tumors in men was
similar to those diagnosed with Barrett’s tumors (64
yr), but the two women with cardia tumors were di-
agnosed in their 50s, at a lower average age than
women with Barrett’s tumors. The mean survival time
for individuals diagnosed with either tumor was ap-
proximately 9 mo. Most of the samples of both
tumor types exhibited positive p53 nuclear accumu-
lation (data not shown), which did not correlate with
presence or absence or distal 17q loss. In fact, in this
relatively small sample, there were no statistically
significant correlations between or identifiable trends
in 17q LOH and patient survival, age, or sex or tu-
mor stage.
DISCUSSION
Our LOH data suggest that one or more putative
genes involved in Barrett’s and gastric cardia adeno-
carcinomas may map to distal 17q, as more than 50%
of tumors studied demonstrated loss at one or more
distal 17q loci. The most common region of loss was
at 17q24–proximal 17q25, represented by loci
D17S2058 and D17S929, suggesting that a critical
gene may lie between these loci. This region of loss
is clearly distinct from and distal to BRCA1, at which
only 12.5% of all the adenocarcinomas demonstrated
loss. The fact that less than 25% loss was seen at 17q
loci flanking the region of highest LOH supports the
hypothesis that loss at D17S2058 and D17S929 prob-
ably does not simply reflect background loss.
Whether this region is a region that is relatively un-
stable in the progression of malignant transforma-
tion of solid tumors rather than the location of a
single putative gene cannot be determined from this
study. However, the previously reported findings of
LOH less than 10% at D17S2058 in other solid tu-
mors, including lung, prostate, breast, and ovarian
adenocarcinomas, suggests that this region is not a
region highly susceptible to breakage in solid tumor
progression [26].
The precise physical distance between these two
distal 17q loci remains somewhat uncertain, given
current information in genomic database reports, as
the loci have not yet been physically mapped with
respect to one another on the same currently avail-
able maps of the region. However, extrapolation of
the loci’s respective locations compared with those
of well-mapped flanking loci suggests that they are
probably approximately 3–4 cM apart, based on re-
cent sex-averaged CEPH-Genethon linkage maps of
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the region [30]. Obviously, further development of
physical and genetic maps in this region is needed
to clarify the distances between these markers and
confirm their orientation with respect to one another.
Other scattered regions of 17q loss in these tumors
may suggest that more than one 17q gene is involved
or may simply reflect random chromosomal insta-
bility in tumor progression.
The highest rates of LOH (more than 30%) were
observed at D17S929 and D17S2058, the same loci
defining the smallest common interval of loss. LOH
at D17S2058 in two of four Barrett’s metaplastic epi-
thelium samples in which the matched Barrett’s ad-
enocarcinoma demonstrated LOH tentatively
suggests that LOH in this region may be an early
event in the pathogenesis of Barrett’s adenocarci-
Figure 1. Summary of data for Barrett’s adenocarcinoma
samples (A) and gastric cardia adenocarcinomas (B). Each
patient’s age at diagnosis, sex, and months of survival after
diagnosis (D = deceased, A = alive) are shown when known.
The TNM stage and type classified by the University of
Michigan’s Surgical Pathology Department are also presented.
For LOH, the loci are listed proximal to distal. Solid boxes indi-
cate loss and open boxes retention of heterozygosity, checked
boxes indicate noninformative results, and vertical bars indi-
cate microsatellite instability. The data for the two intragenic
BRCA1 polymorphic markers are combined.
noma. This LOH in the metaplastic lesion is not as
clean as in the tumor sample, suggesting that the
tumor cells are a clonal population of cells, whereas
the metaplastic cells are not (Figure 3). In one of the
matched sets of normal, metaplastic, and tumor
samples (tumor number 22), the adenocarcinoma
demonstrated loss at three distal 17q loci (SSTR2,
D17S2058, and D17S937), but the matched non-
dysplastic Barrett’s epithelium demonstrated loss
only at D17S2058, further supporting the hypoth-
esis that alterations of a gene in this region may be
an early event. In addition, a matched lung adeno-
carcinoma sample (thought to be a second primary
tumor pathologically) from the patient whose esoph-
ageal sample is number 10 also demonstrated loss at
D17S2058 (data not shown). This may imply that
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Figure 1. (continued).
Figure 2. Examples of LOH analysis at D17S2058, the locus
where the highest rate of loss was observed, in three different
esophageal adenocarcinomas. N, normal sample; T, matched
tumor sample. (A) No loss of heterozygosity as amplification of
the larger and smaller alleles in the tumor sample produced
bands of relatively equal intensities as analyzed by autora-
diography after denaturing polyacrylamide gel electrophore-
sis of the amplified PCR product. (B) Loss of the smaller allele in
this tumor is indicated by the arrow. (C) Loss of the larger allele
in another tumor is noted by the arrow.
Table 2. Overall Rates of Loss in Esophageal and
Gastric Cardia Adenocarcinomas for 17q Loci
No. of tumors with loss/








*LOH for this locus reflects data combining BRCA1 polymorphic
markers.
the lung tumor was actually a metastatic lesion rather
than a primary second tumor in this individual or
that the putative gene may also play a role in lung
adenocarcinomas. We subsequently analyzed 19 ad-
enocarcinomas of the lung for LOH of D17S2058 by
using the same methods described above and did not
find significant loss (less than 10%) in the tumors
we studied. This suggests that it is less likely that
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LOH in this region is a common event in primary
lung adenocarcinomas (unpublished data). Similarly,
prostate adenocarcinomas do not demonstrate 17q25
loss [26]. Thus, LOH in this distal 17q24–proximal
17q25 region is not observed in adenocarcinomas of
different tissue types. This supports our hypotheses
that a specific tumor suppressor gene or genes map
to this particular distal 17q region and that the LOH
we observed in esophageal and gastric cardia tumors
probably does not simply reflect random distal 17q
chromosomal instability associated with generalized
tumor progression. Clearly, continued analysis of
adenocarcinomas for involvement of this putative
distal 17q gene or genes in relationship to involve-
ment of other putative cancer genes is needed to elu-
cidate the hypothesized multistep processes that are
associated with esophageal carcinogenesis. The most
common region of loss in the adenocarcinomas is
clearly proximal to the specific 17q25 region of LOH
previously identified in breast and ovarian tumors
[26], suggesting that different distal 17q genes are
probably involved in these different solid tumors.
The patterns of 17q LOH in Barrett’s and gastric
cardia adenocarcinomas were strikingly similar, sup-
porting the hypothesis that the tumors have similar
molecular mechanisms of development, as previously
proposed [7]. No significant statistical correlations
could be drawn between distal 17q LOH and other
clinicopathological data. Only one of the tumors
analyzed demonstrated loss at all informative 17q
loci, and it was a stage IV gastric cardia adenocarci-
noma that also demonstrated positive p53 protein
nuclear immunoreactivity. Interestingly, five of nine
other stage IV tumors analyzed showed no loss of
17q alleles. That most of the samples were from men
simply reflects the observed population incidence of
these types of esophageal and gastric cardia cancer.
The 17q LOH we observed is within the same gen-
eral region where others have mapped a gene in-
volved in squamous cell carcinoma of the esophagus
associated with autosomal dominant palmoplantar
keratoderma [21–24]. Our region of LOH may be
slightly proximal to the locus they mapped by link-
age analysis. This may reflect the relatively poor
physical mapping of the region to date, may suggest
that two different genes are involved, or may dem-
onstrate a specific area of LOH related to a nearby
culprit gene. Although LOH mapping has clearly fa-
cilitated the ultimate isolation of several putative
tumor suppressor genes [27], gene localization by
LOH mapping has not always been precisely consis-
tent with linkage analysis localization of a gene
within the same 3–4 cM interval, as recently reported
in the mapping and cloning of the patched gene caus-
ing basal cell carcinomas [31]. This may reflect some
limitations in the methodology of accurately assess-
ing LOH or may suggest that the LOH may have oc-
curred in some upstream regulatory region of the
putative gene, altering its expression or function. We
found no 17q LOH in three squamous cell carcino-
mas of the esophagus, which was unexpected (un-
published data). Obviously, analysis of additional
samples is required to support or refute the hypoth-
esis that a tumor suppressor gene involved in spo-
radic primary esophageal squamous cell carcinomas
maps to this region of 17q. However, it is very in-
triguing that the region implicated by linkage analy-
sis is within the same region where we noted the
most common overlapping of loss as well as the high-
est rate of 17q LOH. This may suggest that in the
gene in which germline mutations predispose indi-
viduals to development of an autosomal dominant
syndrome consisting of esophageal cancer associated
with palmoplantar keratoderma, somatic mutations
predispose individuals to sporadic types of esoph-
ageal cancer. The association of cancer predisposi-
tion with syndromes characterized by abnormal
nonmalignant phenotypes has been well described.
An example is Gorlin’s syndrome, which is charac-
terized by a variety of developmental defects and
multiple basal cell carcinomas. Affected patients have
germline mutations in the patched gene. Sporadic
basal cell carcinomas are also associated with somatic
mutations in the patched gene [31].
In summary, LOH analysis of distal 17q loci in
Barrett’s esophageal and gastric cardia adenocarci-
nomas suggested that genetic alterations of distal 17q
may be involved in the pathogenesis of these tu-
mors. The smallest common interval of loss and
Figure 3. Light (A) and dark (B) autoradiograph exposures
of LOH at D17S2058 in esophageal adenocarcinoma sample
number 10. This tumor demonstrated loss only at D17S2058.
Clean loss of the larger allele (arrow) is demonstrated in the
tumor sample (T) when compared with the matched normal
sample (N). The matched metaplastic Barrett’s sample (B) dem-
onstrates decreased intensity of the same larger allele that is
absent in the tumor sample (T), suggesting that some of the
cells from the Barrett’s metaplasia sample (B) had lost this al-
lele but that it is not a clonal population of cells.
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highest rates of loss at D17S929–D17S2058, along
with the early loss detected at D17S2058 in
Barrett’s metaplasia samples, suggested that a pu-
tative tumor suppressor gene may be located near
these distal 17q24–proximal 17q25 loci. To deter-
mine the significance of distal 17q genetic alter-
ations in the pathogenesis of esophageal and gastric
cardia adenocarcinoma, further efforts are under way
to better localize and isolate this putative gene and
analyze its role in esophageal cancer.
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